| pioglitazone / Generic mfg. |
| Ongoing | 3 | 60 | Europe | Pioglitazona, A10BG03, Tablet | Hospital Universitario Araba (Sede Santiago), No | Bipolar disorder Trastorno bipolar, Bipolar disorder Trastorno bipolar, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2004-002466-38: A multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%.52 week extension to a multicenter, double-blind, randomized, active controlled, parallel group study to compare the effect of 12 weeks treatment with LAF237 50 mg BID to 50 mg OD in patients with type 2 diabetes with HbA1c 9-11%. |
|
|
| Ongoing | 3 | 20 | Europe | not established, Actos, LAF 237, 18/270/01-C, not extablished, Actos, not extablished, Actos | Novartis Pharma AG | Diabetes mellitus | | | | |
2005-001218-42: Clinical role of PPAR gamma activator (pioglitazone) in reducing the gastric phlogosis in patiens with istological gastritis. |
|
|
| Ongoing | 3 | 80 | Europe | ACTOS*28CPR 15MG, ACTOS*28CPR 15MG | AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | Treatment of patients with gastric phlogosis (infected by Helicobacter pylori) | | | | |
2012-004100-35: clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, on cardiovascular risk factors and on risk factors for the development of type 2 diabetes Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de riesgo cardiovascular y de desarrollo de diabetes tipo 2. |
|
|
| Ongoing | 3 | 40 | Europe | Metformina, espironolactona, Clorhidrato de pioglitazona, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO, Metformina Sandoz, Aldactone Pfizer, Actos®, LOETTE DIARIO | Fundació per la Recerca i la Docència Sant Joan de Déu, Ministerio de Sanidad y Política Social | Ovarian hyperandrogenism hiperandrogenismo ovárico | | | | |
2015-005092-24: Clinical trial in adolescents with ovarian hyperandrogenism and hyperinsulinemia: Effects on ovulatory function, parameters of chronic inflammation, treatment markers of pronostic and effectiveness and the development of type 2 diabetes. Ensayo clínico en adolescentes con hiperandrogenismo ovárico e hiperinsulinismo: efectos sobre la función ovulatoria, parámetros de inflamación crónica, marcadores de evolución y efectividad del tratamiento y de desarrollo de diabetes tipo 2. |
|
|
| Ongoing | 3 | 40 | Europe | Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO, Metformina Sandoz, Aldactone, Pioglitazona Cinfa, LOETTE DIARIO | FUNDACIÓ SANT JOAN DE DÉU, Ministerio de Sanidad y Política Social | ovarian hyperandrogenism with hyperinsulinaemia hiperandrogenismo ovárico con hiperinsulinismo | | | | |
NCT04885712: A Study to Evaluate the Efficacy and Safety of Pioglitazone 15mg or 30mg Add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin |
|
|
| Completed | 3 | 378 | RoW | Metformin≥1000mg, BR3003D, Pioglitazone 15mg, BR3003A-1, Pioglitazone 30 mg, BR3003B-1, Pioglitazone 15mg Placebo, BR3003A-2, Pioglitazone 30mg Placebo, BR3003B-2, Dapagliflozin 10mg, BR3003C | Boryung Pharmaceutical Co., Ltd | Type2 Diabetes | 09/22 | 03/23 | | |
| Withdrawn | 3 | 40 | US | Pioglitazone 30 mg, Actos, Placebo | State University of New York at Buffalo, National Center for Advancing Translational Sciences (NCATS) | Prostate Cancer, Insulin Resistance, Diabetes Mellitus, Type 2, Androgen Deficiency | 03/23 | 03/23 | | |
NCT05605158: Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis |
|
|
| Not yet recruiting | 3 | 56 | RoW | Pioglitazone 30mg, Empagliflozin 10 MG | Tanta University | Non Alcoholic Steatohepatitis | 05/23 | 11/24 | | |
PIEMONTE, NCT05028140: Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus |
|
|
| Not yet recruiting | 3 | 480 | NA | PIEMONTE, PIEMONTE PLACEBO, EMPAGLIFLOZIN, PLACEBO EMPAGLIFLOZIN, PIOGLITAZONE, PLACEBO PIOGLITAZONE | EMS | Type II Diabetes | 03/26 | 09/26 | | |
RENATO, NCT05946564: A Trial to Evaluate the Efficacy of Pioglitazone to Promote Renal Tolerance in ANCA-associated Vasculitis - Trial |
|
|
| Not yet recruiting | 3 | 126 | NA | Pioglitazone (ACTOS®), Placebo of Pioglitazone | Assistance Publique - Hôpitaux de Paris, Ministry of Health, France | ANCA Associated Vasculitis, Rapidly Progressive Glomerulonephritis, Crescentic Glomerulonephritis | 12/25 | 06/27 | | |
2008-005546-23: Treating Insulin Resistance in patient after Stroke for prevention of stroke and myocardial infarction after ischemic stroke and transient ischemic attack |
|
|
| Ongoing | 2/3 | 500 | Europe | Pioglitazone (Actos), AD-4833, Actos, Actos | Yale University School of Medicine, YALE UNIVERSITY, Yale University School of Medicine, | Insulin resistance in patients who have had a stroke or transient ischaemic attack | | | | |
